Who are Vitamin D and calcium suplementation's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Magnogene ® (magnesium), Calcium and Magnesium, Magnesium sulfate administration, intraperitoneal nebulisation of magnesium sulphate, Magnesium glycinate, Ibandronate+alfacalcidol+calcium.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vitamin-d-and-calcium-suplementation.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Vitamin D and calcium suplementation — Competitive Intelligence Brief

Vitamin D and calcium suplementation (Vitamin D and calcium suplementation) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Mineral supplement. Area: Nutrition and Metabolism.

phase 3 Mineral supplement Nutrition and Metabolism Small molecule Live · refreshed every 30 min

Target snapshot

Vitamin D and calcium suplementation (Vitamin D and calcium suplementation) — Gerencia de Atención Primaria, Albacete. Vitamin D and calcium supplementation works by increasing calcium levels in the body, which is essential for maintaining strong bones and preventing deficiencies.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Vitamin D and calcium suplementation TARGET	Vitamin D and calcium suplementation	Gerencia de Atención Primaria, Albacete	phase 3	Mineral supplement
Magnogene ® (magnesium)	Magnogene ® (magnesium)	University Hospital, Clermont-Ferrand	marketed	Mineral supplement	Magnesium ion (Mg2+)
Calcium and Magnesium	Calcium and Magnesium	Sanofi	marketed	Mineral supplement
Magnesium sulfate administration	Magnesium sulfate administration	University of California, San Francisco	marketed	Electrolyte/mineral supplement; anticonvulsant	NMDA receptor; L-type calcium channel
intraperitoneal nebulisation of magnesium sulphate	intraperitoneal nebulisation of magnesium sulphate	B.P. Koirala Institute of Health Sciences	marketed	Mineral supplement / Anti-inflammatory agent	NMDA receptor (indirect antagonism); local anti-inflammatory pathways
Magnesium glycinate	Magnesium glycinate	CMH Kharian Medical College	marketed	Mineral supplement / Nutritional supplement
Ibandronate+alfacalcidol+calcium	Ibandronate+alfacalcidol+calcium	Chinese University of Hong Kong	marketed	Bisphosphonate + active vitamin D + mineral supplement combination	Farnesyl pyrophosphate synthase (ibandronate); vitamin D receptor (alfacalcidol); calcium channels (calcium)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Mineral supplement class)

Gerencia de Atención Primaria, Albacete · 1 drug in this class
Sanofi · 1 drug in this class
University Hospital, Clermont-Ferrand · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Vitamin D and calcium suplementation — Competitive Intelligence Brief. https://druglandscape.com/ci/vitamin-d-and-calcium-suplementation. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab